Table 3.
Univariate analysis results of overall survival in 97 locally advanced esophageal squamous cell carcinoma patients who received curative concurrent chemoradiotherapy
| Characteristics | No. of patients | Median OS (months) | P value |
|---|---|---|---|
| Age | |||
| < 60 years | 64 (66%) | 17.3 | 0.09 |
| ≥ 60 years | 33 (34%) | 13.1 | |
| T status | |||
| 1 + 2 | 15 (16%) | 19.3 | 0.30 |
| 3 + 4 | 82 (84%) | 13.6 | |
| N status | |||
| 0 + 1 | 32 (33%) | 25.5 | 0.021a |
| 2 + 3 | 65 (67%) | 12.9 | |
| Stage | |||
| II + IIIA + IIIB | 31 (32%) | 19.3 | 0.47 |
| IIIC | 66 (68%) | 13.1 | |
| Grade | |||
| 1 + 2 | 71 (73%) | 15.6 | 0.76 |
| 3 | 26 (27%) | 13.6 | |
| Location | |||
| Upper | 40 (41%) | 19.3 | 0.42 |
| Middle + Lower | 57 (59%) | 13.2 | |
| VEGF Day 0 (Mean: 176 pg/mL) | |||
| < 80 | 33 (34%) | 15.0 | 0.52 |
| > 80 | 64 (66%) | 15.6 | |
| VEGF Day 5 (Mean: 163 pg/mL) | |||
| < 80 | 33 (34%) | 22.6 | 0.06 |
| > 80 | 64 (66%) | 12.0 | |
| VEGF Day 28 (Mean: 195 pg/mL) | |||
| < 80 | 29 (30%) | 21.3 | 0.029a |
| > 80 | 68 (70%) | 12.8 | |
| VEGF Day 5/Day 0 ratio | |||
| < 1 | 52 (54%) | 19.3 | 0.026a |
| > 1 | 45 (46%) | 12.0 | |
| VEGF Day 28/Day 0 ratio | |||
| < 1 | 39 (40%) | 12.9 | 0.43 |
| > 1 | 58 (60%) | 17.6 | |
| VEGF Day 28/Day 5 ratio | |||
| < 1 | 45 (46%) | 20.9 | 0.002a |
| > 1 | 52 (54%) | 8.6 | |
OS overall survival; VEGF vascular endothelial growth factor; HR hazard ratio; CI confidence interval
aStatistically significant